Phase II Study of YL202 to Evaluate Safety and Effectiveness in Adults with Advanced Solid Tumors Including Lung, Colorectal, and Cervical Cancer in China

What this Trial Is About

Researchers are evaluating YL202, an antibody-drug conjugate targeting the HER3 protein, in patients with advanced solid tumors including non-small cell lung cancer, colorectal cancer, and cervical cancer. This multicenter, open-label phase II study in China aims to assess the efficacy, safety, and pharmacokinetics of YL202 in these patients who have received one to two prior lines of systemic therapy. The study includes two periods dose exploration and dose expansion. Participants in the colorectal cancer group will be randomly assigned to one of two dose levels of YL202, which is given as an intravenous infusion over approximately one hour. The trial evaluates YL202s effects and monitors patients throughout these periods. Participants will be followed for up to about three years, with assessments including tumor response measured by objective response rate, progression-free survival, duration and depth of response, overall survival, and safety through adverse event monitoring. Tumor tissue samples and organ function tests will be collected, and patients must comply with scheduled visits and procedures during the study period.

A Study of YL202 in Patients With Advanced Solid Tumors